A preliminary study of microRNA expression in different types of primary melanoma
- PMID: 31479413
- PMCID: PMC7202197
- DOI: 10.17305/bjbms.2019.4271
A preliminary study of microRNA expression in different types of primary melanoma
Abstract
MicroRNAs (miRNAs) have been proven to regulate the development and progression of cancer through various mechanisms. The aim of the present study was to compare miRNA expression between primary melanomas from different sites. We analyzed the expression of 84 miRNAs in 27 primary melanoma and 5 nevus formalin-fixed paraffin-embedded (FFPE) samples using the Human Cancer PathwayFinder miScript miRNA PCR Array. The FFPE samples were obtained from the archives of the Municipal Clinical Emergency Hospital of Timisoara and included 10 cutaneous melanomas, 10 uveal melanomas, 7 mucosal melanomas, and 5 cutaneous nevi. Out of 84 miRNAs, 11 miRNAs showed altered expression in all types of melanoma compared with the nevi. Among these, miR-155-5p, miR-9-5p, miR-142-5p, miR-19a-3p, miR-134-5p, and miR-301a-3p were upregulated, while miR-205-5p, miR-203a-3p, miR-27b-3p, miR-218-5p, and miR-23b-3p were downregulated. The highest similarity in miRNA expression pattern was found between uveal and mucosal melanoma groups, i.e., 15 miRNAs had altered expression in both groups. Overall, we identified several miRNAs with significantly altered expression in primary melanomas, including those reported for the first time in this type of cancer. Among them, mir-9-5p, mir-203a-3p, mir-19a-3p, mir-27b-3p, and mir-218-5p showed altered expression in all three melanoma types vs. nevi. Further research should explore the potential of these miRNAs in melanoma.
Conflict of interest statement
Conflict of interest statement: The authors declare no conflict of interests
Figures







Similar articles
-
Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi.Curr Oncol. 2024 May 17;31(5):2881-2894. doi: 10.3390/curroncol31050220. Curr Oncol. 2024. PMID: 38785501 Free PMC article.
-
MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas.Melanoma Res. 2021 Feb 1;31(1):18-26. doi: 10.1097/CMR.0000000000000709. Melanoma Res. 2021. PMID: 33234848
-
Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.Acta Ophthalmol. 2016 May;94 Thesis 1:1-27. doi: 10.1111/aos.13100. Acta Ophthalmol. 2016. PMID: 27192168
-
Are miRNAs Dynamic Biomarkers in Keratoconus? A Review of the Literature.Genes (Basel). 2022 Mar 25;13(4):588. doi: 10.3390/genes13040588. Genes (Basel). 2022. PMID: 35456395 Free PMC article. Review.
-
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.Arch Pathol Lab Med. 2020 Apr;144(4):500-522. doi: 10.5858/arpa.2019-0561-RA. Epub 2020 Feb 14. Arch Pathol Lab Med. 2020. PMID: 32057276 Review.
Cited by
-
Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi.Curr Oncol. 2024 May 17;31(5):2881-2894. doi: 10.3390/curroncol31050220. Curr Oncol. 2024. PMID: 38785501 Free PMC article.
-
Investigating melanogenesis-related microRNAs as disease biomarkers in vitiligo.Sci Rep. 2022 Aug 8;12(1):13526. doi: 10.1038/s41598-022-17770-3. Sci Rep. 2022. PMID: 35941163 Free PMC article.
-
Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression.Genet Res (Camb). 2022 Jul 7;2022:5671562. doi: 10.1155/2022/5671562. eCollection 2022. Genet Res (Camb). 2022. PMID: 35903462 Free PMC article.
-
MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma.Diagnostics (Basel). 2023 Mar 22;13(6):1205. doi: 10.3390/diagnostics13061205. Diagnostics (Basel). 2023. PMID: 36980512 Free PMC article.
-
A deep learning approach based on multi-omics data integration to construct a risk stratification prediction model for skin cutaneous melanoma.J Cancer Res Clin Oncol. 2023 Nov;149(17):15923-15938. doi: 10.1007/s00432-023-05358-x. Epub 2023 Sep 7. J Cancer Res Clin Oncol. 2023. PMID: 37673824 Free PMC article.
References
-
- Ocanha-Xavier JP, Xavier-Junior JCC, Marques MEA. Melanoma:clinical, evolutive and histopathological characteristics of a series of 136 cases. An Bras Dermatol. 2018;93(3):373–6. https://doi.org/10.1590/abd1806-4841.201⇝0. - PMC - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332. - PubMed
-
- Fechete O, Ungureanu L, Şenilă S, Vornicescu D, Dănescu S, Vasilovici A, et al. Risk factors for melanoma and skin health behaviour:an analysis on Romanian melanoma patients. Oncol Lett. 2019;17(5):4139–44. https://doi.org/10.3892/ol.2018.9737. - PMC - PubMed
-
- Barrett AW, Raja AM. The immunohistochemical identification of human oral mucosal melanocytes. Arch Oral Biol. 1997;42(1):77–81. https://doi.org/10.1016/S0003-9969(96)00113-6. - PubMed
-
- Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(2):105–61. https://doi.org/10.1080/10590500500234970. - PubMed